GENOVA,Inc. FY2027 Q1 Earnings Report

Quick View

Executive Summary

While Revenue continued to achieve strong growth of +64.7% year on year, the operating loss persisted, resulting in earnings that highlight ongoing challenges in the quality of revenue growth and core earnings power. Revenue was ¥30.6B (¥18.6B in the same period of the previous year, +64.7%), Operating Income was ¥-2.2B (¥-1.7B in the same period of the previous year, with the operating loss widening), and Ordinary Income was ¥-2.1B (¥-1.7B in the same period of the previous year). Net Income turned profitable at ¥2.5B (¥-1.0B in the same period of the previous year, +354.2%), but this was primarily due to a temporary boost from extraordinary income of ¥4.98B, mainly attributable to gains on the reversal of stock acquisition rights. As indicated by the operating loss, the Company’s fundamental earnings power remains in a transition phase.

Factors Affecting Earnings

【Revenue】Revenue increased to ¥30.6B, representing year-on-year growth of +64.7%. By segment, Smart Clinic posted substantial revenue growth to ¥9.8B (+43.7%), Dental Distribution added ¥8.2B through new consolidation, and the Medical Platform maintained steady growth at ¥11.4B (+7.3%). The new consolidation of the Dental Distribution business, following the acquisition of shares in Akasaka Dental Materials Co., Ltd., was one of the primary drivers of revenue growth.

【Profit and Loss】Operating Income was ¥-2.2B, with the loss widening from ¥-1.7B in the same period of the previous year. The gross profit margin declined significantly from the previous year to 50.1%, apparently due primarily to the consolidation of low-margin products in the Dental Distribution business. Meanwhile, the SG&A ratio improved significantly from the previous year to 57.4%, indicating progress in cost efficiency. Ordinary Income remained negative at ¥-2.1B; however, following the recognition of extraordinary income of ¥4.98B from gains on the reversal of stock acquisition rights, Profit Before Tax was ¥2.8B and Net Income turned profitable at ¥2.5B (+354.2%). The divergence between Net Income and Ordinary Income is temporary and attributable to extraordinary income; therefore, the results can be characterized as higher revenue but lower earnings on an operating income basis.

Segment Analysis

By segment, the Medical Platform was the largest earnings contributor, recording Operating Income of ¥2.8B (profit margin of 24.5%), although profit declined slightly by -2.4% year on year. Smart Clinic recorded Operating Income of ¥2.0B (profit margin of 20.7%), a substantial increase of +297.4% year on year, as economies of scale became evident. Dental Distribution, a newly consolidated segment, recorded an operating loss of ¥-0.7B (profit margin of -8.5%), with start-up and integration costs weighing on consolidated earnings. Other segments remained stable, recording Operating Income of ¥0.2B (+12.3%). The adjustment for company-wide common expenses increased to ¥-6.5B, exceeding the ¥4.3B in combined profit of the reported segments; this is the primary factor driving consolidated Operating Income into the red.

Key Financial Indicators

【Profitability】The Operating Income margin improved by +2.1pt to -7.3% from -9.4% in the same period of the previous year, but remained negative. The gross profit margin declined significantly to 50.1% due to the change in business mix following the consolidation of Dental Distribution, while the SG&A ratio improved to 57.4%, reflecting progress in cost efficiency. The Net Income margin was 8.2%, but was dependent on extraordinary income; on an ordinary income basis, the Company remained loss-making at -7.0%.【Cash Flow Quality】Cash and deposits stood at ¥50.8B, securing strong liquidity with a current ratio of 263.7%. Accounts receivable increased to ¥23.7B (+27.8% year on year), while accounts payable rose to ¥10.6B (+115.0%), indicating an expansion in working capital reflecting business expansion and M&A activity.【Investment Efficiency】ROE was 4.1%; considering the dependence of Net Income on extraordinary income, recurring capital efficiency can be assessed as limited. Total assets were ¥113.1B (¥102.5B in the same period of the previous year), while goodwill was ¥13.9B, equivalent to 22.7% of net assets of ¥61.5B and within a generally tolerable range.【Financial Soundness】The Equity Ratio declined to 54.4% from 67.3% in the same period of the previous year, but remained at a sound level. Long-term borrowings increased to ¥13.9B, up +124% year on year, indicating that funding for M&A and growth investments is increasingly being financed on a long-term basis.

Cash Flow Analysis

Although a standalone cash flow statement has not been disclosed, an analysis of funding trends based on changes in the balance sheet indicates that cash and deposits were ¥50.8B, a slight decrease from ¥53.2B in the same period of the previous year. The +27.8% increase in accounts receivable and the +115.0% increase in accounts payable indicate an expansion in working capital accompanying the new consolidation of Dental Distribution and business growth. If the collection cycle for trade receivables lengthens while operating losses continue, this could affect cash generation capacity. Long-term borrowings increased by +124.3%, suggesting an approach of financing growth investments and M&A with long-term funding; therefore, short-term liquidity concerns appear limited.

Quality of Earnings

The ¥2.5B Net Income profit was heavily dependent on extraordinary income of ¥4.98B, primarily gains on the reversal of stock acquisition rights, and recurring earnings power has not yet been established, as indicated by the ¥-2.2B operating loss. Non-operating income was ¥0.1B, a minor 0.4% of Revenue, whereas extraordinary income reached approximately 16.3% of Revenue, resulting in a substantial divergence between Ordinary Income of ¥-2.1B and Net Income. Amortization expenses for goodwill are compressing Operating Income, and given the increase in goodwill and intangible assets of approximately +35% year on year, monitoring future amortization expenses and impairment risk will be important in assessing earnings quality.

Earnings Forecast and Guidance

Progress in Q1 toward the full-year plan of Revenue of ¥216.0B, Operating Income of ¥15.7B, and Ordinary Income of ¥15.6B was 14.1% for Revenue, below the simple progress benchmark of 25%. Operating Income was a loss of ¥-2.2B, representing negative progress; achieving the full-year plan will therefore require substantial earnings generation and improved profitability in the second half of the fiscal year. Net Income progress was ¥2.5B/¥11.9B, or approximately 20.9%; however, this is an apparent level of progress supported by extraordinary income, and the likelihood of achieving the plan is difficult to assess without a return to profitability at the operating level. Neither the earnings forecast nor the dividend forecast was revised, with both indicated as “None.”

Shareholder Returns

The Company’s full-year dividend forecast is ¥30.00 per share. The dividend for the same period of the previous year was ¥0. The Payout Ratio against forecast EPS of ¥68.74 is approximately 43.6%. Given cash on hand of ¥50.8B and an Equity Ratio of 54.4%, the Company appears to have sufficient financial capacity to maintain dividends for the time being; however, the fact that operating results remain in the red will be subject to continued monitoring.

Risk Factors

1. Gross margin decline and earnings risk in the Dental Distribution segment: The gross profit margin declined to 50.1%, and Dental Distribution is a loss-making segment with an Operating Income margin of -8.5%. If the absorption of integration and start-up costs is prolonged, improvement in company-wide Operating Income may be delayed.

2. Working capital expansion risk: Accounts receivable and accounts payable increased sharply by +27.8% and +115.0% year on year, respectively, potentially increasing volatility in funding requirements associated with business expansion and M&A. Management of the collection cycle will be a key issue.

3. Impairment risk for goodwill and intangible assets: Goodwill increased to ¥13.9B (+35.1% year on year), while intangible fixed assets rose to ¥14.3B (+35.8%). If the integration benefits of the Dental Distribution business do not materialize as planned, there is a risk of increased amortization expenses and impairment charges.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (it_telecom)

Profitability and Returns

The Operating Income margin is significantly below the industry median, while the Net Income margin exceeds the industry median due to the boost from extraordinary income.

Growth and Capital Efficiency

The Revenue growth rate is substantially above the industry median, positioning the Company as a high-growth player within the industry, including the expansion of consolidation through M&A.

※Source: Compiled by the Company

Key Takeaways from the Financial Results

1. Although the top line achieved outstanding growth of +64.7% even within the industry, the decline in the gross profit margin and continued operating losses indicate that core earnings power remains in a transition phase from growth to monetization.

2. The return to Net Income profitability was largely attributable to the temporary impact of extraordinary income of ¥4.98B, while Ordinary Income remained negative at ¥-2.1B. Trends in operating results will be the key factor in assessing earnings sustainability.

3. The increase in goodwill to ¥13.9B and intangible fixed assets to ¥14.3B indicates progress in the M&A strategy, while the earnings improvement of the Dental Distribution segment and the degree to which company-wide common expenses are absorbed will be key points to monitor in assessing the normalization of future profitability.

Theoretical Share Price (Reference Value)

Sensitivity: ¥454–¥480 at ±1% for the cost of equity, and ¥464–¥471 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---